Assertion Contradicted AI assessment confidence: 95% certainty 4/5 debate potential 3/5

Nuzhna: FDA regulation has continuously increased except during the AIDS crisis

Lada Nuzhna · The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation · Nov 14, 2025 · at 6:15

Lada Nuzhna, a biotech investor, discusses the long-term regulatory trends impacting drug development costs and timelines on The a16z Podcast.

0:00 / 0:20exact quote · 20.7s

▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark

“Since the birth of this industry, we only had increasing regulation over time. I think there was like only one time in history of biotech where we made it easier to develop and approve new drugs. And that was during the ACE crisis where AIDS patients were just laying outside of FDA and demanding drugs to be approved on a more accelerated timeline.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

Since the inception of the biotech industry, drug regulation in the United States has continuously increased, with the AIDS crisis being the sole historical exception where drug approval processes were relaxed.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

The claim asserts that since the inception of the biotech industry, U.S. drug regulation has continuously increased, with the AIDS crisis being the sole historical exception where drug approval processes were relaxed. Historical review of U.S. FDA regulatory history demonstrates that numerous major legislative and regulatory changes outside the AIDS crisis simplified requirements and accelerated drug development and approval. For example, the FDA Modernization Act of 1997 (FDAMA) lowered the statutory efficacy standard by allowing approval based on a single pivotal trial instead of two, and codified Fast Track designations. The 21st Century Cures Act of 2016 allowed the use of real-world evidence and surrogate endpoints while streamlining trial designs. Additionally, the FDA Modernization Act 2.0 of 2022 eliminated mandatory animal testing requirements for Investigational New Drug (IND) applications. Consequently, the AIDS crisis was far from the sole exception.

FDA Modernization Act of 1997 (FDAMA) lowered the statutory efficacy standard to allow approval based on a single trial plus confirmatory evidence rather than two independent Phase 3 trials.
21st Century Cures Act of 2016 incorporated Real-World Evidence, surrogate endpoints, and streamlined clinical trial design requirements.
FDA Modernization Act 2.0 of 2022 ended the statutory mandate requiring animal testing prior to human clinical trials for IND applications.

Checked against

[1] nih.gov [2] everycrsreport.com [3] kivo.io [4] nih.gov [5] nih.gov [6] cancerresearch.org [7] fda.gov [8] wikipedia.org

FDAMA 1997 section 115 "substantial evidence" single clinical investigation "Fast Track" "Breakthrough Therapy" "Accelerated Approval" regulatory requirements simplified reduced FDA history FDA Modernization Act 1997 21st Century Cures Act 2016 Orphan Drug Act 1983 drug approval requirements simplified reduced US FDA drug approval history legislation PDUFA FDAMA 21st Century Cures drug approval requirements "FDA Modernization Act of 1997" "one clinical trial" OR "single clinical trial" OR "confirmatory evidence" "FDA Modernization Act 2.0" animal testing mandate 2022

assessed as of 2026-07-31

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

biotech industry FDA

⚑ Spot an error? Report it

More from Lada Nuzhna

Assertion Not checkable as stated

Nuzhna: China leads global development in in vivo CAR-T and gene editing

“They are now leading in, in VivoC RTs, they are leading in gene editing and gene therapy, and partially due to this ability to do those investigator-initiated trials.”

Lada Nuzhna Nov 14, 2025 ▶ 17:09 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

Prediction Not checkable as stated

Nuzhna: AI will solve open biology questions before predicting drug efficacy

“Many big bio problems and open questions will be solved with AI way before we can predict efficacy for drugs.”

Lada Nuzhna Nov 14, 2025 ▶ 25:23 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

Prediction Not checkable as stated

Nuzhna: AI virtual cell models are near realization with existing data

“Virtual cells is actually not that far out. I think we have all the necessary data to generate something like that.”

Lada Nuzhna Nov 14, 2025 ▶ 25:33 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

Insight

Nuzhna: New therapeutic modalities face a "better than the Beatles" bottleneck

“So I think many new modalities will be bottlenecked by the Beatles, better than the Beatles problem.”

Lada Nuzhna Nov 14, 2025 ▶ 31:56 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

Insight

Nuzhna: US multi-payer insurance system disincentivizes early preventive healthcare

“The payer that pays the most for diseases of aged population is Medicare which kicks in after 65. Before then we have a multi-payer system where patients Tend to rotate their insurance every few years. And so there's really not much incentive for someone to co…”

Lada Nuzhna Nov 14, 2025 ▶ 34:49 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

Prediction Not checkable as stated

Nuzhna: Medicine will treat aging before understanding its underlying mechanisms

“I think we would be able to treat aging before we understand how to measure it or what it is or why it happens.”

Lada Nuzhna Nov 14, 2025 ▶ 40:24 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

Nuzhna: FDA regulation has continuously increased except during the AIDS crisis

More from Lada Nuzhna

Turn any episode into a week of clips.